clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
In chronic myeloid leukemia (CML), the constitutively activated tyrosine kinase BCR-ABL1, the fusion protein resultant from t(9;22)(q34;q11), confers proliferation of myeloid progenitors. Additional chromosomal abnormalities, such as þ 8, i(17q) or t(3;21), are found in 7-10% of CML patients at diagnosis or may appear during disease progression. 1 One of the most common rearrangements in acute myeloid leukemia (AML) is the t(8;21)(q22;q22) leading to the fusion of RUNX1 (alias, AML1) exon 5 to RUNX1T1 (alias, ETO) exon 2. Although it is conceivable that the proliferative benefit contributed by BCR-ABL1 and the impaired ability for differentiation conferred by RUNX1-RUNX1T1 could promote leukemia, these aberrations only rarely coexist in vivo. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] We report two patients with BCR-ABL1-positive CML and co-occurrence of RUNX1-RUNX1T1. Strikingly, in both cases a not previously described RUNX1-RUNX1T1 transcript was identified, which is due to the fusion of RUNX1 exon 6 (instead of exon 5) to RUNX1T1 exon 2.
Patient 1, a 54-year-old male, was diagnosed with CML in chronic phase in 2008. The white blood cell (WBC) count was 120 000/ml, and no peripheral blood (PB) blasts and no abnormal blast expansion in the bone marrow (BM) were observed. The karyotype, as assessed in 25 metaphases from BM, was 46,XY, Accepted article preview online 21 February 2013; advance online publication, 12 April 2013 Letters to the Editor t(9;22)(q34;q11). The BCR-ABL1 transcript was detected in BM with a ratio of 72.8% relative to ABL1. The patient was initiated on treatment with imatinib 400 mg daily and achieved complete hematologic response. After 14 months, he developed hematologic relapse, with WBC of 4800/ml, comprising 1% blasts, 2% promyelocytes and 22% eosinophils. In the BM, 15% blasts, which had a strong expression of CD117 (KIT), were detected, and the karyotype was 45,XY,t(8;21)(q22;q22),t(9;22)(q34;q11), À 11 [1] /93,XXYY, þ 8, þ 8,t(8;21)(q22;q22)x2, t(9;22)(q34;q11)x2, À 11 [8] . Twenty-four color fluorescence in-situ hybridization (FISH) on BM confirmed the presence of both translocations (data not shown); interphase FISH revealed BCR-ABL1 and RUNX1-RUNX1T1 rearrangements in B90% of the nuclei. BCR-ABL1 transcript was detected with a ratio of 37.1% and RUNX1-RUNX1T1 with 10.3% relative to ABL1 in the PB. No RUNX1-RUNX1T1 was detected in retrospective analyses of samples collected during chronic phase. The patient received dasatinib 70 mg daily and underwent allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-identical sibling 3 months later. He is currently in ongoing complete hematologic and molecular remission.
Patient 2, a 30-year-old male, was diagnosed with CML in 2010. He had WBC of 30 000/ml and no blast expansion in the BM, but extramedullary infiltration of sacral vertebrae 1 and 2, based on which the CML was considered as being in blast phase. No The results provided in the reports suggest that patients expressed the transcript usually observed in t(8;21) acute myeloid leukemia (AML) (RUNX1-RUNXT1 amplicon had the same size as in AML or positive control). c The t(8;21) genomic breakpoint was located in RUNX1 intron 6; RUNX1 exon 6-RUNX1T1 was not confirmed in analyses on transcript level.
d,e Chronic myeloid leukemia was considered in blast phase based on the presence of myeloid sarcomas. Karyotypes depicted are from bone marrow (BM). f On the basis of the clinical information and the karyotype provided in the respective reports, patient 9 may be identical with patient 7.
Letters to the Editor karyotype was assessed at diagnosis, but BCR-ABL1 was detected with 47.1% in the PB. The patient was initiated on imatinib 400 mg daily and achieved complete hematologic response. After 3 months, the patient relapsed, and nilotinib 800 mg daily was started. BM at relapse revealed the following karyotype: 48-49,XY, þ 8,t(8;21)(q22;q22),t(9;22)(q34;q11), þ der(21)t(8;21) (q22;q22), þ der(22)t(9;22)(q34;q11)[cp4]; twenty-four color FISH on BM confirmed both translocations (Supplementary Figure S1) . Retrospective analyses of RUNX1-RUNX1T1 revealed its presence with a ratio of 5.3% in the PB at the diagnosis. The patient underwent HLA-mismatched unrelated allogeneic HSCT, but died 4 months later due to sepsis.
A systematic review of the literature recorded on PubMed and search of the Mitelman database of chromosome aberrations and gene fusions in cancer unveiled 11 patients who were diagnosed with CML and cytogenetic clones harboring both t(9;22) and t(8;21) ( Table 1) . Considering these patients and those of the present study, all 13 had CML in accelerated or blast phase at time of detection of t(8;21). In contrast, none of the 6 patients with a karyotype available also in chronic phase harbored a t(8;21). This indicates that the occurrence of RUNX1-RUNX1T1 in addition to BCR-ABL1 strongly associates with an advanced stage of disease. In accordance with this observation, cytogenetic aberrations in addition to t(9;22) and t(8;21) were reported in 10 of 13 patients. Importantly, at the time of the detection of t(8;21), more than 90% of the metaphases analyzed per patient displayed both t(9;22) and t(8;21) in 10 of 11 patients with available data. This clearly implies an additional growth advantage conferred by t (8;21) .
To what extent the treatment with tyrosine kinase inhibitors (TKI) contributed to the acquisition of t(8;21) remains elusive, considering the fact that only few CML cases with t(8;21) are described, and that the gain of t(8;21) was also observed in patients not treated with TKIs. However, TKIs may be an option in the treatment of CML patients harboring both t(9;22) and t(8;21). The patient described by Hsiao et al.
11 had a major cytogenetic response under nilotinib, and, in the present study, patient 2 achieved a complete hematologic response with imatinib. However, as responses are not durable, TKIs may rather be used as bridge to an allogeneic HSCT.
The primers we used to screen for RUNX1-RUNX1T1 were located in RUNX1 exon 5 and RUNX1T1 exon 2, which are the exons usually fused by t(8;21) in AML. When we assessed RUNX1-RUNX1T1 in patient 1 and 2, we observed that the amplicons were larger than those usually observed in t(8;21) AML (Figure 1) . We sequenced the amplicons and found a fusion of RUNX1 exon 6 to RUNX1T1 exon 2 in both patients (Figure 1 ). On the basis of the nucleotide sequence, the deduced amino acid sequence was in-frame, and the predicted weight of the full-length fusion protein was B94 kDa.
To our knowledge, no study has described the fusion of RUNX1 exon 6 to RUNX1T1 exon 2. A previously reported CML patient harboring the t(8;21) had a genomic breakpoint in RUNX1 intron 6, which deducedly results in the fusion of RUNX1 exon 6 to RUNX1T1, but the authors did not confirm this on transcript level (Table 1) . 7, 8 Overall, RUNX1 exon 6 appears to be only rarely fused to RUNX1 exon 2, as the two cases presented in this study were the only ones with PCR results demonstrating such a fusion among 135 RUNX1-RUNX1T1-positive AML patients tested by the Munich Leukemia Laboratory. Interestingly, another translocation, that is, t(3;21)-(q26;q22), which leads to the fusion of RUNX1 to MECOM (alias, MDS1 and EVI1 complex locus), and is described to be acquired during the progression of CML, can also involve exon 6 of RUNX1.
13
The biological relevance of RUNX1 exon 6 in RUNX1-RUNX1T1 is at present unclear. RUNX1 exon 6 encodes the negative regulatory region of DNA binding, which inhibits the association of RUNX1 with DNA. Moreover, exon 6 encodes arginine residues the methylation of which by PRMT1 (protein arginine N-methyltransferase1) promotes transcriptional activity of RUNX1.
14 These data suggest that the RUNX1-RUNX1T1 variant observed in the present study may differ from the one usually encoded by the t(8;21) by its transcriptional activity.
It has been reported that the expression of an alternatively spliced isoform of RUNX1-RUNX1T1 containing exon 9a of RUNX1T1 is necessary for the development of AML in mice. 15 To gain insights into the biological impact of the RUNX1-RUNX1T1 variant described here, we determined whether the transcript includes this alternative exon (for methods, see Supplementary  Table S1 ). Indeed, transcripts including RUNX1T1 exon 9a were expressed in addition to those not containing exon 9a in patient 2 (data not shown); the material of patient 1 was insufficient for the analyses.
In summary, we present two rare but apparently recurrent genetic features in myeloid leukemia. One is the co-occurrence of BCR-ABL1 and RUNX1-RUNX1T1, which may be associated with a progressive state of CML, as also recently reviewed by Najfeld et al. 12 The second is a novel variant of RUNX1-RUNX1T1 that includes exon 6 of RUNX1 and appears to be co-operating with BCR-ABL1 in the same clone. In addition to the potential biological relevance, our findings underline the significance of performing cytogenetic and molecular studies in CML patients not restricted to BCR-ABL1, particularly at acceleration or relapse of the disease.
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